Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14654
ICD10 33 N41 N41.9
ICD9CM 35 601 601.9
MeSH 42 D011472
NCIt 47 C26866
UMLS 69 C0033581

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostate cancer and prostate carcinoma in situ, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cardiovascular system

Wikipedia : 72 Prostatitis (less commonly prostatosis) is inflammation of the prostate gland. Prostatitis is classified... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 859)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 33.5 KLK3 MSMB NKX3-1 PROS1 TGFB1 VDR
2 prostate carcinoma in situ 31.5 IL10 IL1B IL6 TNF
3 atrophy of prostate 30.8 CXCL8 IL10 IL1B IL6 TNF
4 kaposi sarcoma 30.7 IL1B IL6 TNF
5 papilledema 29.5 IL6 TNF
6 melioidosis 29.2 IL10 IL6 TNF
7 cataract 29.2 IL1B TNF
8 urticaria 29.1 PDE5A TGFB1
9 ulcerative colitis 29.1 IL10 IL6 TNF
10 alopecia 29.0 CXCL8 IL10 IL6 TNF
11 lymphoma 28.8 IL10 IL1B IL6 TNF
12 breast disease 28.5 CXCL8 IL1B IL6 TNF
13 hypertrichosis 28.4 IL1B IL6 TNF
14 hepatitis b 28.4 CXCL8 IL10 TNF
15 myeloid sarcoma 28.3 CXCL8 IL1B IL6 TNF
16 dysphagia 28.1 CXCL8 IL10 IL6 TNF
17 sinusitis 28.1 CXCL8 IL1B TGFB1 TNF
18 pyelonephritis 28.0 CXCL8 IL10 IL1B TNF
19 churg-strauss syndrome 27.6 CXCL8 IL10 IL1B TNF
20 choroiditis 27.5 CXCL8 IL10 IL1B IL6 TNF
21 myocardial infarction 27.4 IL10 IL1B IL6 PDE5A TNF
22 colon adenocarcinoma 27.2 CXCL8 IL10 IL1B IL6 TNF
23 atherosclerosis 27.0 CXCL8 IL10 IL1B IL6 TNF
24 pulmonary embolism 26.9 CXCL8 IL10 IL1B IL6 TNF
25 rheumatoid arthritis 26.4 CXCL8 IL10 IL1B IL6 TGFB1 TNF
26 prostate disease 12.3
27 prostate cancer 1 12.2
28 prostate adenocarcinoma 12.1
29 prostate stromal sarcoma 12.1
30 prostate cancer, hereditary, 13 12.1
31 prostate cancer, hereditary, 2 12.1
32 prostate rhabdomyosarcoma 12.1
33 prostate sarcoma 12.1
34 prostate cancer, hereditary, 11 12.1
35 prostate cancer, hereditary, 12 12.1
36 prostate leiomyosarcoma 12.0
37 prostate angiosarcoma 12.0
38 prostate embryonal rhabdomyosarcoma 12.0
39 prostate calculus 12.0
40 prostatic adenoma 11.9
41 adenosquamous prostate carcinoma 11.9
42 prostatic hypertrophy 11.9
43 prostate small cell carcinoma 11.8
44 prostate lymphoma 11.8
45 prostatic cyst 11.8
46 nodular prostate 11.8
47 prostate leiomyoma 11.8
48 prostate transitional cell carcinoma 11.8
49 prostatic malacoplakia associated with prostatic abscess 11.8
50 prostate cancer susceptibility 11.8

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Chronic Myocardial Ischemia Epididymo-Orchitis
Ischemic Heart Disease Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 TGFB1 TNF ADRA1A CXCL8 IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 TNF ADRA1A CXCL8 IL10 IL1B TGFB1

MGI Mouse Phenotypes related to Prostatitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 TGFB1 TNF VDR ADRA1A IL10 IL1B
2 endocrine/exocrine gland MP:0005379 9.91 IL10 IL6 MSMB NKX3-1 TGFB1 TNF
3 digestive/alimentary MP:0005381 9.88 IL10 IL6 NKX3-1 TGFB1 TNF VDR
4 integument MP:0010771 9.87 IL10 IL1B IL6 PROS1 TGFB1 TNF
5 muscle MP:0005369 9.8 ADRA1A IL10 IL6 PROS1 TGFB1 TNF
6 neoplasm MP:0002006 9.7 IL10 IL1B IL6 MSMB NKX3-1 TGFB1
7 reproductive system MP:0005389 9.5 IL10 IL6 MSMB NKX3-1 TGFB1 TNF
8 skeleton MP:0005390 9.17 TNF VDR IL10 IL1B IL6 NKX3-1

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Cycloserine Approved Phase 4,Phase 3 68-41-7 401 6234
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
4
Methyltestosterone Approved Phase 4 58-18-4 6010
5
Testosterone Approved, Investigational Phase 4 58-22-0 6013
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Cilastatin Approved Phase 4 82009-34-5 5280454 6435415
10
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
11 Prulifloxacin Investigational Phase 4,Phase 2 123447-62-1
12
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
13 Cholinergic Agents Phase 4,Phase 3,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
16 Analgesics Phase 4,Phase 3,Phase 2
17 Anti-Anxiety Agents Phase 4,Phase 3
18 Anticonvulsants Phase 4,Phase 3
19 calcium channel blockers Phase 4,Phase 3
20 Calcium, Dietary Phase 4,Phase 3,Phase 2
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
22 Psychotropic Drugs Phase 4,Phase 3
23 Tranquilizing Agents Phase 4,Phase 3
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antitubercular Agents Phase 4,Phase 3
28 Fluoroquinolones Phase 4,Phase 3,Phase 2
29 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
30 Permixon Phase 4,Phase 3
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
32 Antimetabolites Phase 4,Phase 3
33 Renal Agents Phase 4,Phase 3,Phase 2
34 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
35 Botulinum Toxins Phase 4,Phase 3,Phase 2
36 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
37 Neuromuscular Agents Phase 4,Phase 3,Phase 2
38 onabotulinumtoxinA Phase 4,Phase 3,Phase 2
39 Androgens Phase 4,Phase 3,Early Phase 1
40 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
41 Hormones Phase 4,Phase 3,Early Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
43 Anabolic Agents Phase 4
44 Antineoplastic Agents, Hormonal Phase 4
45 Pharmaceutical Solutions Phase 4,Phase 3
46 Testosterone 17 beta-cypionate Phase 4
47
Testosterone enanthate Phase 4 315-37-7 9416
48 Testosterone undecanoate Phase 4
49 Phosphodiesterase 5 Inhibitors Phase 4
50 Phosphodiesterase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 66)

id Name Status NCT ID Phase Drugs
1 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
3 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
4 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
5 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Active, not recruiting NCT02366975 Phase 4 Testosterone gel 2%
6 Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
7 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
8 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
9 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
10 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
11 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
12 Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Completed NCT00260637 Phase 2, Phase 3
13 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
14 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin;levofloxacin;levofloxacin
15 A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Completed NCT00236808 Phase 3 levofloxacin
16 Levofloxacin, Chronic Bacterial Prostatitis Completed NCT00277511 Phase 3 Levofloxacin
17 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00103402 Phase 3 Alfuzosin
18 Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Completed NCT00169585 Phase 3 Levofloxacin oral tablets
19 Complementary and Alternative Medicine for Urological Symptoms(CAMUS) Completed NCT00603304 Phase 3 Saw Palmetto - first 24 weeks;Placebo - first 24 weeks;Saw Palmetto - weeks 24 - 48;Placebo - weeks 24 - 48;Saw Palmetto - weeks 48 - 72;Placebo - weeks 48 - 72
20 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
21 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
22 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
23 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
24 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
25 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
26 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
27 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT00529386 Phase 2 Botox;Lidocaine
28 An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland Completed NCT00236990 Phase 2 pentosan polysulfate sodium
29 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2 Tanezumab;Placebo
30 A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT01391338 Phase 2 ASP3652;Placebo
31 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2 Norfloxacin;Placebo
32 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
33 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
34 Prulifloxacin in Chronic Bacterial Prostatitis (CBP) Recruiting NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
35 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
36 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
37 Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis Unknown status NCT00913315 tolterodine;tamsulosin;placebo
38 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
39 Non Interventional Study of Levofloxacin in Chronic Prostatitis Completed NCT02711943 Levofloxacin 500
40 Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome Completed NCT00922012
41 Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis Completed NCT01098279
42 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
43 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Completed NCT01826617
44 Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury Completed NCT01601041
45 Diagnostic Challenges in IC (and Male CPPS) Completed NCT00672087
46 2013 Annual National Digital Rectal Exam (DRE) Day Study Completed NCT01886547
47 Linkage Analysis in Interstitial Cystitis Completed NCT00675298
48 Observational Study of Control Participants for the MAPP Research Network Completed NCT01098292
49 Physical Therapy Trial for Pelvic Pain Completed NCT00434343
50 Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome Completed NCT00710073

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

39
Prostate, Bone, Endothelial, Lymph Node, Testes, Lung, T Cells

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 21735)
id Title Authors Year
1
Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility. ( 28373430 )
2017
2
Nonspecific granulomatous prostatitis in association with eosinophilic epithelial metaplasia and prostatic adenocarcinoma. ( 28937384 )
2017
3
Alterations in regional homogeneity of resting-state cerebral activity in patients with chronic prostatitis/chronic pelvic pain syndrome. ( 28926645 )
2017
4
Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. ( 27410686 )
2017
5
MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. ( 28350134 )
2017
6
Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer. ( 28068638 )
2017
7
MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. ( 27956179 )
2017
8
Effects of testosterone and 17I^a89estradiol on angiotensina89induced changes in tyrosine kinase activity in the androgena89independent human prostate cancer cell line, DU145. ( 28949385 )
2017
9
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer. ( 28085790 )
2017
10
Health care costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. ( 28534659 )
2017
11
Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. ( 28389666 )
2017
12
Incidental Prostate Adenocarcinoma in Cystoprostatectomy Specimens: Partial Versus Complete Prostate Sampling. ( 28381150 )
2017
13
Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele. ( 28176139 )
2017
14
Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. ( 28091563 )
2017
15
Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. ( 28272245 )
2017
16
Head-To-Head Comparison Between High- and Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis. ( 28952806 )
2017
17
Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERI+. ( 27696457 )
2017
18
Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. ( 28533399 )
2017
19
Association of estrogen receptor I+ PvuII and XbaI polymorphisms with prostate cancer susceptibility and risk stratification: a meta-analysis from case-control studies. ( 28721070 )
2017
20
Facial Paralysis and Hearing Loss: A Rare Manifestation of Prostate Cancer Metastases. ( 28409073 )
2017
21
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
22
Activation of GPR30 stimulates GTP-binding of GI+i1 protein to sustain activation of Erk1/2 in inhibition of prostate cancer cell growth and modulates metastatic properties. ( 27908592 )
2017
23
High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. ( 27921521 )
2017
24
Repression of MicroRNA-372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2. ( 27730751 )
2017
25
Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis. ( 28704753 )
2017
26
BCL2A genotypes and prostate cancer survival. ( 28396899 )
2017
27
Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer. ( 27679555 )
2017
28
Malakoplakia of the Prostate as a Mimicker of Prostate Cancer on Prostate Health Index and Magnetic Resonance Imaging-Fusion Prostate Biopsy: A Case Report. ( 28736746 )
2017
29
PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion. ( 27756608 )
2017
30
Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer. ( 28358701 )
2017
31
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
32
Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. ( 28534214 )
2017
33
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. ( 28614217 )
2017
34
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
35
miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. ( 28122308 )
2017
36
Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. ( 27931798 )
2017
37
Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas. ( 27913052 )
2017
38
CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. ( 28130224 )
2017
39
Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. ( 28282546 )
2017
40
Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclinA D1 and MMP-7. ( 27922675 )
2017
41
Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. ( 28631332 )
2017
42
Commensal bacterial modulation of the host immune response to ameliorate pain in a murine model of chronic prostatitis. ( 28715352 )
2017
43
c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells. ( 28394299 )
2017
44
Concurrent Diffuse Pyelonephritis and Prostatitis: Discordant Findings on Sequential FDG PET/CT and 67Ga SPECT/CT Imaging. ( 27824318 )
2017
45
Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2. ( 27921232 )
2017
46
Xanthogranulomatous Prostatitis, a Rare Prostatic Entity. ( 27800297 )
2017
47
Active Surveillance of Prostate Cancer. ( 28090626 )
2017
48
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? ( 28191651 )
2017
49
Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer. ( 27815387 )
2017
50
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. ( 28384067 )
2017

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 CXCL8 IL10 IL1B IL6 TGFB1 TNF
2
Show member pathways
13.3 CXCL8 IL10 IL1B IL6 TGFB1 TNF
3
Show member pathways
13.24 CXCL8 IL10 IL1B IL6 TGFB1 TNF
4
Show member pathways
12.88 CXCL8 IL10 IL1B IL6 TGFB1 TNF
5
Show member pathways
12.85 CXCL8 IL10 IL1B IL6 TGFB1 TNF
6 12.66 CXCL8 IL6 KLK3 NKX3-1 TGFB1
7
Show member pathways
12.64 IL1B IL6 TGFB1 TNF
8
Show member pathways
12.59 IL10 IL1B IL6 TGFB1 TNF
9
Show member pathways
12.54 IL10 IL1B IL6 TNF
10
Show member pathways
12.45 IL10 IL1B IL6 TGFB1 TNF
11
Show member pathways
12.32 CXCL8 IL1B IL6 TNF
12
Show member pathways
12.26 CXCL8 IL1B IL6 TNF
13
Show member pathways
12.25 IL10 IL1B TGFB1 TNF
14
Show member pathways
12.18 CXCL8 IL1B IL6 TNF
15
Show member pathways
12.17 CXCL8 IL10 IL1B IL6 TNF
16 12.16 IL10 IL1B IL6 TGFB1 TNF VDR
17 12.09 CXCL8 IL10 IL1B IL6 NKX3-1 TNF
18
Show member pathways
12.07 IL6 KLK3 TGFB1
19
Show member pathways
12.04 IL10 IL6 TGFB1
20 12.03 CXCL8 IL1B IL6 TGFB1 TNF
21 12.01 IL6 TGFB1 TNF
22 12 IL1B TGFB1 TNF
23 11.97 CXCL8 IL1B IL6 TGFB1
24 11.95 IL10 IL6 TNF
25
Show member pathways
11.95 IL10 IL1B IL6 TGFB1 TNF
26 11.91 IL1B IL6 TNF
27 11.9 CXCL8 IL1B IL6 TGFB1 TNF
28
Show member pathways
11.88 IL1B IL6 TGFB1
29 11.87 IL1B IL6 TNF
30 11.85 CXCL8 IL1B TNF
31 11.85 CXCL8 IL1B IL6 TGFB1 TNF
32
Show member pathways
11.84 CXCL8 IL6 TGFB1
33 11.8 CXCL8 IL1B IL6
34 11.79 CXCL8 IL10 IL1B IL6 TGFB1 TNF
35 11.77 IL10 IL1B TNF
36 11.76 IL10 IL6 TGFB1 TNF
37 11.76 CXCL8 IL10 IL1B IL6 TNF
38 11.74 IL10 IL1B IL6 TGFB1 TNF
39
Show member pathways
11.69 CXCL8 IL1B IL6 TNF
40 11.63 CXCL8 IL1B IL6 TNF
41 11.62 CXCL8 IL10 IL1B IL6 TGFB1 TNF
42 11.57 CXCL8 IL6 TGFB1
43 11.57 CXCL8 IL1B IL6 TGFB1 TNF
44 11.53 IL1B TGFB1 TNF
45 11.53 IL1B KLK3 TNF
46 11.53 IL1B IL6 TNF VDR
47
Show member pathways
11.44 IL10 TGFB1 TNF
48 11.41 CXCL8 IL10 IL1B IL6 TNF
49 11.39 IL10 IL1B IL6 TNF
50 11.38 IL10 IL1B IL6 TNF

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CXCL8 IL10 IL1B IL6 KLK3 MSMB
2 extracellular space GO:0005615 9.28 CXCL8 IL10 IL1B IL6 KLK3 MSMB

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.99 ADRA1A IL10 IL6 TGFB1
2 leukocyte migration GO:0050900 9.95 IL1B PROS1 TGFB1 TNF
3 positive regulation of transcription, DNA-templated GO:0045893 9.93 IL10 IL1B IL6 NKX3-1 TGFB1 TNF
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 ADRA1A IL6 TGFB1 TNF
5 aging GO:0007568 9.91 ADRA1A IL10 IL6 TGFB1
6 cellular response to tumor necrosis factor GO:0071356 9.88 CXCL8 IL6 NKX3-1
7 positive regulation of protein phosphorylation GO:0001934 9.87 IL1B NKX3-1 TGFB1 TNF
8 response to organic substance GO:0010033 9.86 IL10 TGFB1 TNF
9 positive regulation of protein kinase B signaling GO:0051897 9.86 IL6 TGFB1 TNF
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 IL6 TGFB1 TNF
11 cellular response to organic cyclic compound GO:0071407 9.85 IL1B TGFB1 TNF
12 inflammatory response GO:0006954 9.85 CXCL8 IL10 IL1B IL6 TGFB1 TNF
13 cellular response to interleukin-1 GO:0071347 9.84 CXCL8 IL6 NKX3-1
14 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 IL1B IL6 TGFB1 TNF
16 positive regulation of MAP kinase activity GO:0043406 9.82 PDE5A TGFB1 TNF
17 cell growth GO:0016049 9.81 ADRA1A IL6 TGFB1
18 cellular response to lipopolysaccharide GO:0071222 9.8 CXCL8 IL10 IL6 TNF
19 positive regulation of gene expression GO:0010628 9.8 IL1B IL6 NKX3-1 TGFB1 TNF VDR
20 negative regulation of fat cell differentiation GO:0045599 9.79 IL6 TGFB1 TNF
21 positive regulation of interleukin-6 production GO:0032755 9.79 IL1B IL6 TNF
22 positive regulation of cell division GO:0051781 9.76 IL1B NKX3-1 TGFB1
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.75 IL1B IL6 TNF
24 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.73 IL10 IL1B IL6 TNF
25 positive regulation of NF-kappaB import into nucleus GO:0042346 9.71 IL1B TNF
26 positive regulation of histone acetylation GO:0035066 9.71 IL1B TGFB1
27 embryonic digestive tract development GO:0048566 9.71 CXCL8 TNF
28 negative regulation of lipid catabolic process GO:0050995 9.71 IL1B TNF
29 positive regulation of chemokine production GO:0032722 9.71 IL6 TNF
30 negative regulation of T cell proliferation GO:0042130 9.71 IL10 PDE5A TGFB1
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IL1B TNF
32 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 TNF
33 cellular response to hepatocyte growth factor stimulus GO:0035729 9.7 IL10 IL6
34 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.69 IL1B TNF
35 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 IL10
36 lipopolysaccharide-mediated signaling pathway GO:0031663 9.69 IL1B TGFB1 TNF
37 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
38 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
39 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
40 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
42 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
43 sequestering of triglyceride GO:0030730 9.6 IL1B TNF
44 positive regulation of mononuclear cell migration GO:0071677 9.59 TGFB1 TNF
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 IL1B TNF
46 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
47 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IL1B TNF
48 protein kinase B signaling GO:0043491 9.46 IL1B NKX3-1 TGFB1 TNF
49 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.43 IL6 NKX3-1 TNF
50 negative regulation of mitotic cell cycle GO:0045930 9.26 IL10 NKX3-1 TGFB1 TNF

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CXCL8 IL10 IL1B IL6 TGFB1 TNF

Sources for Prostatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....